Company: ATRA
Filing Date: 2025-05-15
Form Type: 8-K
Source: 0001193125-25-120345
Chunk: 1

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-05-15
Form: 8-K
Item: Item 5.02
Chunk 1
---
Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

In connection with the Company’s offer and sale of 834,237 shares of common stock at an offering price of $6.61 per share and pre-fundedwarrants to purchase 1,587,108 shares of common stock at an offering price of $6.6099 per share in an underwritten registered direct offering to a limited number of existing institutional investors, including entities affiliated with Panacea Venture (“ Panacea”), Redmile Group (“ Redmile”), EcoR 1 Capital and Adiumentum Capital Management pursuant to an underwriting agreement entered into with TD Securities (USA) LLC, as representative to the underwriters, dated as of May 14, 2025 (the “ Offering”), on May 14, 2025, the Board of Directors of the Company (the “ Board”) approved the appointment of, to be effective immediately following the completion of the Offering, James Huang and Nachi Subramanian to serve as members of the Board, with initial terms expiring at the Company’s 2027 annual meeting of stockholders. Mr. Huang is the founder and Managing Director of Panacea. Mr. Subramanian is a Managing Director at Redmile. The Offering is expected to close on May 16, 2025, subject to customary closing conditions.

The Board has not appointed Mr. Huang or Mr. Subramanian to any Board committee. Except for the Offering, there are no arrangements or understandings between the Company and Mr. Huang or Mr. Subramanian and any other persons pursuant to which each was selected as a director of the Company. The Board has determined that each of Mr. Huang and Mr. Subramanian is independent under the Company’s Corporate Governance Guidelines, applicable SEC requirements and Nasdaq listing standards. Except for the Offering, there is no transaction involving any of Mr. Huang or Mr. Subramanian that requires disclosure under Item 404(a) of Regulation S-K. Each of Mr. Huang and Mr. Subramanian has elected not to receive compensation under the Company’s non-employeedirector compensation policy. The Company expects to enter into its standard form of indemnification agreement with each of Mr. Huang and Mr. Subramanian.